Clinical Trials Browser

Prostatic Neoplasms, Castration-Resistant

Lymphoma, Large B-Cell, Diffuse

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Lymphoma, Follicular

Prostate Cancer Metastatic

Prostatic Neoplasms

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

Lymphoma, Follicular, Recurrence

Prostatic Neoplasms

Metastatic Castration-sensitive Prostate Cancer

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Follicular, Recurrence

Lymphoma, Large B-Cell, Diffuse

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Lymphoma, Follicular

Lymphoma, T-Cell, Peripheral

Lymphoma, Follicular

Lymphoma, T-Cell, Peripheral

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Lymphoma, Non-Hodgkin

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Multiple Myeloma

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Metastatic Castrate Resistant Prostate Cancer

Limb-girdle muscular dystrophy, type 2C, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin

Breast Neoplasms

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Lymphoma, Non-Hodgkin

Clinical Trials

MAGNITUDE

MK-2140-010

MK-2400-001

KLK2-PASenger

OLYMPIA-1

OMAHA-003

MK-5684-004

EPCORE™FL-2

LEDA

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

AMPLITUDE

GOLSEEK-1

POLARIX

OLYMPIA-2

OLYMPIA-3

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

CONTACT-02

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

CRESCENDO

ZUMA-22

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

frontMIND

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

KEYNOTE-921

CYCLONE 3

CheckMate 7DX

IPATential150

SELENE

KEYLYNK-010

ERA 223

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

CHRONOS-4

DEB

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

KEYNOTE-921

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

ROBUST

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

ECHELON-2

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)